Cargando…

Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods

Owing to several mutations, the oncogene Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is activated in the majority of cancers, and targeting it has been pharmacologically challenging. In this study, using an in silico approach comprised of pharmacophore modeling, molecular docking, and molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, Apoorva M., Kumar, Vikas, Parate, Shraddha, Lee, Gihwan, Yoon, Sanghwa, Lee, Keun Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836163/ https://www.ncbi.nlm.nih.gov/pubmed/35163234 http://dx.doi.org/10.3390/ijms23031309

Ejemplares similares

Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2
por: Kumar, Vikas, et al.
Publicado: (2021)

Computational Simulations Highlight the IL2Rα Binding Potential of Polyphenol Stilbenes from Fenugreek
por: Kulkarni, Apoorva M., et al.
Publicado: (2022)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Computational Approaches to Discover Novel Natural Compounds for SARS‐CoV‐2 Therapeutics
por: Rampogu, Shailima, et al.
Publicado: (2021)

Computer-Aided Drug Discovery Identifies Alkaloid Inhibitors of Parkinson's Disease Associated Protein, Prolyl Oligopeptidase
por: Kulkarni, Apoorva M., et al.
Publicado: (2021)

In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics
por: Rana, Rabia Mukhtar, et al.
Publicado: (2020)

Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies
por: Rampogu, Shailima, et al.
Publicado: (2020)

3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors
por: Kumar, Vikas, et al.
Publicado: (2022)

Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer
por: Danishuddin,, et al.
Publicado: (2021)

Exploring the Binding Interaction of Raf Kinase Inhibitory Protein With the N-Terminal of C-Raf Through Molecular Docking and Molecular Dynamics Simulation
por: Parate, Shraddha, et al.
Publicado: (2021)

Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations
por: Kumar, Vikas, et al.
Publicado: (2021)

Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches
por: Kumar, Vikas, et al.
Publicado: (2023)

Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
por: Ramalingam, Prasanna Srinivasan, et al.
Publicado: (2023)

Investigation of Marine-Derived Natural Products as Raf Kinase Inhibitory Protein (RKIP)-Binding Ligands
por: Parate, Shraddha, et al.
Publicado: (2021)

Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics
por: Parate, Shraddha, et al.
Publicado: (2022)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics
por: Rana, Rabia Mukhtar, et al.
Publicado: (2019)

Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy
por: Issahaku, Abdul Rashid, et al.
Publicado: (2022)

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation
por: Wang, Yuting, et al.
Publicado: (2022)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Conditional Knockout of N-WASP Enhanced the Formation of Keratinizing Squamous Cell Carcinoma Induced by KRas(G12D)
por: Kalailingam, Pazhanichamy, et al.
Publicado: (2023)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders
por: Zeb, Amir, et al.
Publicado: (2019)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023)

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
por: Stites, Edward C., et al.
Publicado: (2018)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry
por: Singh, Pooja, et al.
Publicado: (2022)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o3ame8d6fjq330aegium3rrs4b